Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
Authors:
Open Access
- 22 September 2008
- journal article
- research article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 62 (11) , 1664-1674
Abstract
Patient perception of overactive bladder (OAB) treatment outcomes can be a useful indicator of benefit and may help drive persistence on treatment, which is known to be poor in OAB. It remains unclear whether OAB patients dissatisfied with one antimuscarinic can achieve satisfaction with another and supporting data are limited. This study investigated patient-reported outcomes and clinical parameters during darifenacin treatment in OAB patients who expressed dissatisfaction with prior extended-release (ER) oxybutynin or tolterodine therapy (administered for >or= 1 week within the past year). This open-label study was conducted in darifenacin-naïve OAB patients. Patients received 7.5 mg darifenacin once daily with the possibility of up-titrating to 15 mg after 2 weeks, for up to 12 weeks. Efficacy parameters included the Patient's Perception of Bladder Condition (PPBC), patient satisfaction with treatment, micturition frequency and number of urgency and urge urinary incontinence (UUI) episodes. Adverse events (AEs) were also recorded. In total, 497 patients were treated (84.1% women). Darifenacin treatment resulted in statistically significant improvements in PPBC scores, micturition frequency, urgency and UUI episodes from baseline at 12 weeks. The improvements were similar for patients previously treated with oxybutynin ER or tolterodine ER. More than 85% of patients expressed satisfaction with darifenacin. As noted in other studies, the most common AEs were dry mouth and constipation, but these infrequently resulted in treatment discontinuation, which was low overall. In this study, PPBC score and OAB symptoms were significantly improved, and satisfaction was high during treatment with darifenacin (7.5/15 mg) in patients who were dissatisfied with the previous antimuscarinic treatment.Keywords
This publication has 11 references indexed in Scilit:
- Persistence, Adherence, and Switch Rates Among Extended-Release and Immediate-Release Overactive Bladder Medications in a Regional Managed Care PlanJournal of Managed Care Pharmacy, 2008
- Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trialCurrent Medical Research and Opinion, 2007
- Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT)Clinical Therapeutics, 2006
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 2006
- Long‐term treatment with darifenacin for overactive bladder: results of a 2‐year, open‐label extension studyBJU International, 2006
- Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatmentUrology, 2006
- Patient-reported outcomes in overactive bladder: The influence of perception of condition and expectation for treatment benefitUrology, 2006
- The Validation of the Patient Perception of Bladder Condition (PPBC): A Single-Item Global Measure for Patients with Overactive BladderEuropean Urology, 2006
- An investigation of dose titration with darifenacin, an M 3 ‐selective receptor antagonistBJU International, 2005
- Functional Selectivity of Muscarinic Receptor Antagonists for Inhibition of M3-Mediated Phosphoinositide Responses in Guinea Pig Urinary Bladder and Submandibular Salivary GlandThe Journal of Pharmacology and Experimental Therapeutics, 2004